




AULA VIRTUAL de RADIOFARMACIA

Plataforma Virtual de Formación Continua en Radiofarmacia

www.aulavirtualradiofarmacia.es

INFORMA

Lectura recomendada



Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide Treatment

JNM, June 2001

Helmut R. Maecke¹ and Jean Claude Reubi²

¹Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany; and ²Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Berne, Switzerland.

For correspondence or reprints contact: Helmut R. Maecke, Department of Nuclear Medicine, University Hospital Freiburg, Hugstetterstrasse 55, D-79106 Freiburg, Germany. E-mail: helmut.maecke@uniklinik-freiburg.de

Radiolabeled peptides have been an important class of compounds in radiopharmaceutical sciences and nuclear medicine for more than 20 years. Despite strong research efforts, only somatostatin-based radiopeptides have a real impact on patient care, diagnostically and therapeutically. [¹¹¹In-diethylenetriaminepentaacetic acid⁰]octreotide is commercially available for imaging. Imaging was highly improved by the introduction of PET radionuclides such as ⁶⁸Ga, ⁶⁴Cu, and ¹⁸F. Two peptides are successfully used in targeted radionuclide therapy when bound to DOTA and labeled with ⁹⁰Y and ¹⁷⁷Lu.



Colabora con Farmacéuticos Mundi (**FarmaMundi**) (<http://www.farmaceuticosmundi.org/>)



FARMA
MUNDI
FARMACEUTICOS
MUNDI